Difference between revisions of "Non-small cell lung carcinoma"

Jump to navigation Jump to search
no edit summary
 
(24 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{ Infobox diagnosis
{{ Infobox diagnosis
| Name      = {{PAGENAME}}
| Name      = {{PAGENAME}}
| Image      =  
| Image      = Non-small cell lung carcinoma -- high mag.jpg
| Width      =
| Width      =
| Caption    =  
| Caption    = Non-small cell lung carcinoma. [[H&E stain]].
| Synonyms  = large cell carcinoma (term discouraged in the context of biopsies & FNAs)
| Synonyms  = large cell carcinoma (term discouraged in the context of biopsies & FNAs)
| Micro      =
| Micro      =
| Subtypes  =
| Subtypes  = NSCC favour adenocarcinoma, NSCC favour squamous cell carcinoma, NSCC-not otherwise specified
| LMDDx      = [[lung adenocarcinoma]], [[squamous cell carcinoma of the lung|lung squamous carcinoma]], [[lung small cell carcinoma]], poorly differentiated metastatic [[carcinoma]]
| LMDDx      = [[lung adenocarcinoma]], [[squamous cell carcinoma of the lung|lung squamous carcinoma]], [[lung small cell carcinoma]], poorly differentiated metastatic [[carcinoma]], other poorly differentiated neoplasms
| Stains    =
| Stains    =
| IHC        = pankeratin +ve, [[CD56]] -ve, chromogranin A -ve, synaptophysin -ve  
| IHC        = pankeratin +ve, [[CD56]] -ve, chromogranin A -ve, synaptophysin -ve, [[TTF-1]] +ve/-ve, [[p63]] +ve/-ve  
| EM        =
| EM        =
| Molecular  =
| Molecular  =
Line 19: Line 19:
| Assdx      =
| Assdx      =
| Syndromes  =
| Syndromes  =
| Clinicalhx = typically no history of malignancy
| Clinicalhx = no history of malignancy or no suspicion of recurrence
| Signs      =
| Signs      =
| Symptoms  =
| Symptoms  = +/-hemopytsis, +/-dyspnea
| Prevalence = uncommon
| Prevalence = uncommon
| Bloodwork  =
| Bloodwork  =
Line 31: Line 31:
| Tx        = surgery if feasible
| Tx        = surgery if feasible
}}
}}
'''Non-small cell [[lung]] carcinoma''', abbreviated '''NSCLC''', is a malignant epithelial neoplasm of the lung that is ''not'' [[small cell carcinoma of the lung]].   
'''Non-small cell lung carcinoma''', abbreviated '''NSCLC''', is a [[carcinoma|malignant epithelial neoplasm]] of the [[lung]] that is ''not'' [[small cell carcinoma of the lung]].   


It is umbrella term that includes [[squamous cell carcinoma of lung]], [[adenocarcinoma of the lung]] and [[adenosquamous carcinoma of the lung]].<ref>{{Cite journal  | last1 = Song | first1 = Z. | last2 = Lin | first2 = B. | last3 = Shao | first3 = L. | last4 = Zhang | first4 = Y. | title = Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma. | journal = J Chin Med Assoc | volume = 76 | issue = 9 | pages = 481-5 | month = Sep | year = 2013 | doi = 10.1016/j.jcma.2013.05.007 | PMID = 23769878 }}</ref>
It is umbrella term that includes [[squamous cell carcinoma of lung]], [[adenocarcinoma of the lung]] and [[adenosquamous carcinoma of the lung]].<ref>{{Cite journal  | last1 = Song | first1 = Z. | last2 = Lin | first2 = B. | last3 = Shao | first3 = L. | last4 = Zhang | first4 = Y. | title = Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma. | journal = J Chin Med Assoc | volume = 76 | issue = 9 | pages = 481-5 | month = Sep | year = 2013 | doi = 10.1016/j.jcma.2013.05.007 | PMID = 23769878 }}</ref>
Line 37: Line 37:
It is also known as '''large cell carcinoma'''; however, usage of ''large cell carcinoma'' is discouraged in the context of lung biopsies and [[pulmonary cytopathology|lung cytopathology]] specimens.<ref name=pmid22970842>{{Cite journal  | last1 = Travis | first1 = WD. | last2 = Brambilla | first2 = E. | last3 = Noguchi | first3 = M. | last4 = Nicholson | first4 = AG. | last5 = Geisinger | first5 = K. | last6 = Yatabe | first6 = Y. | last7 = Ishikawa | first7 = Y. | last8 = Wistuba | first8 = I. | last9 = Flieder | first9 = DB. | title = Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. | journal = Arch Pathol Lab Med | volume = 137 | issue = 5 | pages = 668-84 | month = May | year = 2013 | doi = 10.5858/arpa.2012-0263-RA | PMID = 22970842 }}</ref>  
It is also known as '''large cell carcinoma'''; however, usage of ''large cell carcinoma'' is discouraged in the context of lung biopsies and [[pulmonary cytopathology|lung cytopathology]] specimens.<ref name=pmid22970842>{{Cite journal  | last1 = Travis | first1 = WD. | last2 = Brambilla | first2 = E. | last3 = Noguchi | first3 = M. | last4 = Nicholson | first4 = AG. | last5 = Geisinger | first5 = K. | last6 = Yatabe | first6 = Y. | last7 = Ishikawa | first7 = Y. | last8 = Wistuba | first8 = I. | last9 = Flieder | first9 = DB. | title = Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. | journal = Arch Pathol Lab Med | volume = 137 | issue = 5 | pages = 668-84 | month = May | year = 2013 | doi = 10.5858/arpa.2012-0263-RA | PMID = 22970842 }}</ref>  


In the clinical context, it is usually referred to as '''non-small cell lung cancer'''; this ignores the fact that not all non-small cell lung cancer fits into the carcinoma category.
In the clinical context, it is often referred to as '''non-small cell lung cancer'''; this ignores the fact that not all non-small cell lung cancer fits into the [[carcinoma]] category.


''Poorly differentiated carcinoma of the lung'' and ''poorly differentiated lung carcinoma'' redirect to this article.
''Poorly differentiated carcinoma of the lung'', ''non-small cell carcinoma'' and ''poorly differentiated lung carcinoma'' redirect to this article.


==General==
==General==
Line 49: Line 49:
Clinical:
Clinical:
*Radiologic findings should not be suggestive of a metastasis.
*Radiologic findings should not be suggestive of a metastasis.
*No history of malignancy or no suspicion of recurrence.
*+/-Hemopytsis.
*+/-Dyspnea.


==Microscopic==
==Microscopic==
Line 62: Line 65:
*Large cell variant of [[small cell carcinoma of the lung]].
*Large cell variant of [[small cell carcinoma of the lung]].
*[[Lung metastasis]] - imaging suggestive of a metastasis or a history of malignancy.
*[[Lung metastasis]] - imaging suggestive of a metastasis or a history of malignancy.
*[[Malignant melanoma]].
*Other poorly differentiated neoplasms
===Grading===
*''NSCC-NOS'', ''NSCC favour adenocarcinoma'', ''NSCC favour SCC'' are grade 4.
Note:
*In a large series of patients, there is no statistical difference in survival been grade 3 and grade 4.<ref name=pmid16678584>{{Cite journal  | last1 = Sun | first1 = Z. | last2 = Aubry | first2 = MC. | last3 = Deschamps | first3 = C. | last4 = Marks | first4 = RS. | last5 = Okuno | first5 = SH. | last6 = Williams | first6 = BA. | last7 = Sugimura | first7 = H. | last8 = Pankratz | first8 = VS. | last9 = Yang | first9 = P. | title = Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. | journal = J Thorac Cardiovasc Surg | volume = 131 | issue = 5 | pages = 1014-20 | month = May | year = 2006 | doi = 10.1016/j.jtcvs.2005.12.057 | PMID = 16678584 }}</ref>
===Images===
<gallery>
Image: Non-small cell lung carcinoma -- low mag.jpg | NSCLC - low mag. (WC)
Image: Non-small cell lung carcinoma -- intermed mag.jpg | NSCLC - intermed mag. (WC)
Image: Non-small cell lung carcinoma -- high mag.jpg | NSCLC - high mag. (WC)
Image: Non-small cell lung carcinoma -- very high mag.jpg | NSCLC - very high mag. (WC)
Image: Non-small cell lung carcinoma - alt -- very high mag.jpg | NSCLC - very high mag. (WC)
</gallery>


==IHC==
==IHC==
Line 69: Line 89:


Note:
Note:
*Immunostains should not favour adenocarcinoma or squamous cell carcinoma - see ''Sloan-Kettering algorithm'' below.
*If immunostains favour adenocarcinoma or squamous cell carcinoma, the case should be sign as ''favour adenocarcinoma'' or ''favour squamous cell carcinoma'', see ''Sloan-Kettering algorithm'' below and ''Sign out'' section.


===Adenocarcinoma versus squamous carcinoma===
===Adenocarcinoma versus squamous carcinoma===
Sloan-Kettering algorithm - Rekhtman ''et al.'':<ref name=pmid21623384>{{Cite journal  | last1 = Rekhtman | first1 = N. | last2 = Ang | first2 = DC. | last3 = Sima | first3 = CS. | last4 = Travis | first4 = WD. | last5 = Moreira | first5 = AL. | title = Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. | journal = Mod Pathol | volume = 24 | issue = 10 | pages = 1348-59 | month = Oct | year = 2011 | doi = 10.1038/modpathol.2011.92 | PMID = 21623384 }}</ref>
Memorial Sloan-Kettering algorithm - Rekhtman ''et al.'':<ref name=pmid21623384>{{Cite journal  | last1 = Rekhtman | first1 = N. | last2 = Ang | first2 = DC. | last3 = Sima | first3 = CS. | last4 = Travis | first4 = WD. | last5 = Moreira | first5 = AL. | title = Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. | journal = Mod Pathol | volume = 24 | issue = 10 | pages = 1348-59 | month = Oct | year = 2011 | doi = 10.1038/modpathol.2011.92 | PMID = 21623384 }}</ref>
{| class="wikitable sortable"  
{| class="wikitable sortable"  
! TTF-1\p63  
! TTF-1\p63  
Line 96: Line 116:


==Sign out==
==Sign out==
International consensus terminology - Travis ''et al''.:<ref name=pmid22970842>{{Cite journal  | last1 = Travis | first1 = WD. | last2 = Brambilla | first2 = E. | last3 = Noguchi | first3 = M. | last4 = Nicholson | first4 = AG. | last5 = Geisinger | first5 = K. | last6 = Yatabe | first6 = Y. | last7 = Ishikawa | first7 = Y. | last8 = Wistuba | first8 = I. | last9 = Flieder | first9 = DB. | title = Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. | journal = Arch Pathol Lab Med | volume = 137 | issue = 5 | pages = 668-84 | month = May | year = 2013 | doi = 10.5858/arpa.2012-0263-RA | PMID = 22970842 }}</ref>
{| class="wikitable sortable"
! Diagnosis
! Stains
|-
| Non-small cell carcinoma, favour adenocarcinoma
| [[TTF-1]] or napsin +ve
|-
| Non-small cell carcinoma, favour squamous cell carcinoma
| [[p40]] or [[p63]] +ve
|-
| Non-small cell carcinoma-not otherwise specified
| -ve NE stains, -ve SCC stains, -ve adenoca stains
|}
===Not otherwise specified===
<pre>
<pre>
Lung, Left Lower Lobe, Core Biopsy:  
Lung, Left Lower Lobe, Core Biopsy:  
- POORLY DIFFERENTIATED CARCINOMA, see comment.  
- NON-SMALL CELL CARCINOMA-NOT OTHERWISE SPECIFIED, see comment.  


COMMENT:  
COMMENT:  
Line 108: Line 144:
squamous cell carcinoma.   
squamous cell carcinoma.   


The neuroendocrine markers (chromogranin A, synaptophysin, CD56) and the squamoid
The neuroendocrine markers (chromogranin A, synaptophysin, CD56) and the squamous
markers available (p63, CK5/6) are negative; thus, the tumour is not further classified.  
markers (p63, CK5/6) are negative; thus, the tumour is not further classified.
</pre>
 
===Favour squamous===
<pre>
Lung, Left Upper Lobe, Core Biopsy:
- NON-SMALL CELL CARCINOMA, favour squamous cell carcinoma, see comment.
 
Comment:
The tumour stains as follows:
POSITIVE: AE1/AE3, CK5/6, CK7.
NEGATIVE: TTF-1, napsin A, p63, CDX2, CK20, S-100.
 
EGFR/ALK testing has been ordered.
 
The immunostains favour squamous cell carcinoma.
</pre>
</pre>


48,479

edits

Navigation menu